Download PDF
Z Gastroenterol 2021; 59(04): 345-359
DOI: 10.1055/a-1372-5595
Leitlinie

S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Register Nr. 021-031 – Stand: 07.01.21

Federführende Fachgesellschaft:
Frank Tacke
1   Charité Universitätsmedizin Berlin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Charité Mitte/Campus Virchow-Klinikum, Berlin, Deutschland
,
Markus Cornberg
2   Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover; Centre for individualised infection Medicine (CiiM), Hannover; Deutsches Zentrum für Infektionsforschung (DZIF), Deutschland
,
Martina Sterneck
3   Universitätsklinikum Hamburg-Eppendorf, I. Medizinische Klinik und Poliklinik, Hamburg, Deutschland
,
Jonel Trebicka
4   Universitätsklinikum Frankfurt, Medizinische Klinik I, Frankfurt, Deutschland
,
Utz Settmacher
5   Universitätsklinikum Jena, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Jena, Deutschland
,
Wolf Otto Bechstein
6   Universitätsklinikum Frankfurt, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Frankfurt, Deutschland
,
Thomas Berg
7   Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie, Bereich Hepatologie, Leipzig, Deutschland
,
Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), vertreten durch Frank Tacke, Markus Cornberg, Martina Sterneck, Jonel Trebicka, Thomas Berg, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), vertreten durch Wolf Bechstein, Deutsche Transplantationsgesellschaft (DTG), vertreten durch Utz Settmacher, Die Leitlinie wird von der Deutschen Gesellschaft für Pneumologie (DGP) unterstützt › Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Lebertransplantationsprogramme und Lebertransplantation

1. Welche Anpassungen sollten für die Durchführung von Organentnahmen und Lebertransplantationen während der COVID-19-Pandemie vorgenommen werden?


#

Supplement



Publication History

Article published online:
12 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Richtlinien zur Organtransplantation gem. § 16 TPG. Dtsch Arztebl 2019; DOI: 10.3238/arztebl.2019.rili_baek_OrgaWlOvLeberT.
    CrossrefPubMedGoogle Scholar
  • 2 Tacke F, Kroy DC, Barreiros AP. et al. Liver transplantation in Germany. Liver Transplant 2016; 22: 1136-1142
    CrossrefPubMedGoogle Scholar
  • 3 Ritschl PV, Nevermann N, Wiering L. et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach. Am J Transplant 2020; 20: 1826-1836
    CrossrefPubMedGoogle Scholar
  • 4 Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol 2020; 73: 441-445
    CrossrefPubMedGoogle Scholar
  • 5 Zaidan M, Legendre C. Solid organ transplantation in the era of COVID-19. Transplantation 2020; DOI: 10.1097/tp.0000000000003536.
    CrossrefPubMedGoogle Scholar
  • 6 Goff RR, Wilk AR, Toll AE. et al. Navigating the COVID‐19 pandemic: Initial impacts and responses of the Organ Procurement and Transplantation Network in the United States. Am J Transplant 2020; DOI: 10.1111/ajt.16411.
    CrossrefPubMedGoogle Scholar
  • 7 Boettler T, Marjot T, Newsome PN. et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Reports 2020; 2: 100169
    CrossrefPubMedGoogle Scholar
  • 8 Rouphael C, D’Amico G, Ricci K. et al. Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose. Am J Transplant 2020; DOI: 10.1111/ajt.16330.
    CrossrefPubMedGoogle Scholar
  • 9 Kates OS, Fisher CE, Rakita RM. et al. Emerging evidence to support not always “just saying no” to SARS-CoV-2 positive donors. Am J Transplant 2020; 20: 3261-3262
    CrossrefPubMedGoogle Scholar
  • 10 Kates OS, Fisher CE, Rakita RM. et al. Use of SARS-CoV-2-infected deceased organ donors: Should we always “just say no?”. Am J Transplant 2020; 20: 1787-1794
    CrossrefPubMedGoogle Scholar
  • 11 Shah MB, Lynch RJ, El-Haddad H. et al. Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2-positive donors. Am J Transplant 2020; 20: 1795-1799
    CrossrefPubMedGoogle Scholar
  • 12 Cho HJ, Koo JW, Roh SK. et al. COVID-19 transmission and blood transfusion: A case report. J Infect Public Health 2020; 13: 1678-1679
    CrossrefPubMedGoogle Scholar
  • 13 Toyoda H, Huang DQ, Le MH. et al. Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic. Hepatol Commun 2020; 4: 1751-1757
    CrossrefPubMedGoogle Scholar
  • 14 Gruttadauria S. Preliminary Analysis of the Impact of the Coronavirus Disease 2019 Outbreak on Italian Liver Transplant Programs. Liver Transplant 2020; 26: 941-944
    CrossrefPubMedGoogle Scholar
  • 15 Aghemo A, Masarone M, Montagnese S. et al. Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. Dig Liver Dis 2020; 52: 937-941
    CrossrefPubMedGoogle Scholar
  • 16 Bajaj JS, Garcia-Tsao G, Biggins SW. et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut 2020; DOI: gutjnl-2020-322118.
    CrossrefPubMedGoogle Scholar
  • 17 Moreau R, Jalan R, Gines P. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144
    PubMedGoogle Scholar
  • 18 Gerbes AL, Labenz J, Appenrodt B. et al. Updated S2k-Guideline Complications of liver cirrhosis. German Society of Gastroenterology (DGVS). Z Gastroenterol 2019; 57: 611-680
    PubMedGoogle Scholar
  • 19 Marjot T, Moon AM, Cook JA. et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol 2020; DOI: 10.1016/j.jhep.2020.09.024.
    CrossrefPubMedGoogle Scholar
  • 20 Iavarone M, D’Ambrosio R, Soria A. et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 2020; 73: 1063-1071
    CrossrefPubMedGoogle Scholar
  • 21 Kluge S, Janssens U, Welte T. et al. German recommendations for critically ill patients with COVID‑19. Medizinische Klin – Intensivmed und Notfallmedizin 2020; DOI: 10.1007/s00063-020-00689-w.
    CrossrefPubMedGoogle Scholar
  • 22 Boettler T, Newsome PN, Mondelli MU. et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Reports 2020; 2: 100113
    CrossrefPubMedGoogle Scholar
  • 23 Rosenblatt R, Verna EC. COVID 19: Management of Decompensated Cirrhosis and Liver Transplant Recipients. Clin Liver Dis 2020; 15: 200-203
    CrossrefPubMedGoogle Scholar
  • 24 Reuken PA, Rauchfuss F, Albers S. et al. Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic. Am J Transplant 2020; 20: 3042-3050
    CrossrefPubMedGoogle Scholar
  • 25 De Franchis R, Abraldes JG, Bajaj J. et al. Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 743-752
    PubMedGoogle Scholar
  • 26 Kim D, Adeniji N, Latt N. et al. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol 2020; DOI: 10.1016/j.cgh.2020.09.027.
    CrossrefPubMedGoogle Scholar
  • 27 Martini S, Patrono D, Pittaluga F. et al. Urgent Liver Transplantation Soon After Recovery From COVID‐19 in a Patient With Decompensated Liver Cirrhosis. Hepatol Commun 2020; DOI: 10.1002/hep4.1580.
    CrossrefPubMedGoogle Scholar
  • 28 Soin AS, Choudhary NS, Yadav SK. et al. Restructuring Living-Donor Liver Transplantation at a High-Volume Center During the COVID-19 Pandemic. J Clin Exp Hepatol 2020; DOI: 10.1016/j.jceh.2020.09.009.
    CrossrefPubMedGoogle Scholar
  • 29 Alconchel F, Cascales-Campos PA, Pons JA. et al. Severe COVID-19 after liver transplantation, surviving the pitfalls of learning on-the-go: Three case reports. World J Hepatol 2020; 12: 870-879
    CrossrefPubMedGoogle Scholar
  • 30 Lagana SM, de Michele S, Lee MJ. et al. Covid-19-Associated hepatitis complicating recent living donor liver transplantation. Arch Pathol Lab Med 2020; 144: 929-932
    CrossrefPubMedGoogle Scholar
  • 31 Passarelli VC, Perosa AH, de Souza Luna LK. et al. Detected SARS-CoV-2 in Ascitic Fluid Followed by Cryptococcemia: a Case Report. SN Compr Clin Med 2020; 2: 2414-2418
    CrossrefPubMedGoogle Scholar
  • 32 Angeli P, Bernardi M, Villanueva C. et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460
    CrossrefPubMedGoogle Scholar
  • 33 Lazzaroni MG, Piantoni S, Masneri S. et al. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev 2020; DOI: 10.1016/j.blre.2020.100745.
    CrossrefPubMedGoogle Scholar
  • 34 Levi M, Thachil J, Iba T. et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7: e438-e440
    CrossrefPubMedGoogle Scholar
  • 35 Søgaard KK, Horváth-Puhó E, Grønbæk H. et al. Risk of venous thromboembolism in patients with liver disease: A nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101
    CrossrefPubMedGoogle Scholar
  • 36 Thachil J, Tang N, Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 1023-1026
    CrossrefPubMedGoogle Scholar
  • 37 Spyropoulos AC, Anderson FA, FitzGerald G. et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140: 706-714
    CrossrefPubMedGoogle Scholar
  • 38 Nendaz M, Spirk D, Kucher N. et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism: Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost 2014; 111: 531-538
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Turco L, de Raucourt E, Valla D-C. et al. Anticoagulation in the cirrhotic patient. JHEP Reports 2019; 1: 227-239
    CrossrefPubMedGoogle Scholar
  • 40 Loffredo L, Pastori D, Farcomeni A. et al. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology 2017; 153: 480-487.e1
    CrossrefPubMedGoogle Scholar
  • 41 Tritschler T, Mathieu ME, Skeith L. et al. Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost 2020; 18: 2958-2967
    CrossrefPubMedGoogle Scholar
  • 42 Lemos ACB, do Espírito Santo DA, Salvetti MC. et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359-366
    CrossrefPubMedGoogle Scholar
  • 43 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med 2020; 383: 1813-1826
    CrossrefPubMedGoogle Scholar
  • 44 Pan H, Peto R, Henao-Restrepo A-M. WHO Solidarity Trial Consortium. et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med 2020; DOI: 10.1056/NEJMoa2023184.
    CrossrefPubMedGoogle Scholar
  • 45 Aleissa MM, Silverman EA, Paredes Acosta LM. et al. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. Antimicrob Agents Chemother 2020; DOI: 10.1128/aac.01814-20.
    CrossrefPubMedGoogle Scholar
  • 46 Goldman JD, Lye DCB, Hui DS. et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020; 383: 1827-1837
    CrossrefPubMedGoogle Scholar
  • 47 Adamsick ML, Gandhi RG, Bidell MR. et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol 2020; 31: 1384-1386
    CrossrefPubMedGoogle Scholar
  • 48 Horby P, Lim WS, Emberson J. et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. N Engl J Med 2020; DOI: 10.1101/2020.06.22.20137273.
    CrossrefPubMedGoogle Scholar
  • 49 Sterne JAC, Murthy S, Diaz JV. et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis. JAMA – J Am Med Assoc 2020; 324: 1330-1341
    CrossrefPubMedGoogle Scholar
  • 50 Rawson TM, Moore LSP, Zhu N. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa530.
    CrossrefPubMedGoogle Scholar
  • 51 Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. J Hepatol 2014; 61: 1385-1396
    CrossrefPubMedGoogle Scholar
  • 52 Chai KL, Valk SJ, Piechotta V. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane database Syst Rev 2020; 10: CD013600
    PubMedGoogle Scholar
  • 53 McCashland TM, Preheim LC, Gentry-Nielsen MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181: 757-760
    CrossrefPubMedGoogle Scholar
  • 54 Aggeletopoulou I, Davoulou P, Konstantakis C. et al. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol 2017; 27
    PubMedGoogle Scholar
  • 55 Leise MD, Talwalkar JA. Immunizations in chronic liver disease: What should be done and what is the evidence. Curr Gastroenterol Rep 2013; 15
    PubMedGoogle Scholar
  • 56 Härmälä S, Parisinos CA, Shallcross L. et al. Effectiveness of influenza vaccines in adults with chronic liver disease: A systematic review and meta-analysis. BMJ Open 2019; 9
    PubMedGoogle Scholar
  • 57 Polack FP, Thomas SJ, Kitchin N. et al Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; DOI: NEJMoa2034577.
    CrossrefPubMedGoogle Scholar
  • 58 FDA. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document – FDA. 2020 Im Internet: moz-extension://10ea96ff-bc03-1b4a-8497-ddb699a0f082/enhanced-reader.html?openApp&pdf=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F144434%2Fdownload
    PubMedGoogle Scholar
  • 59 Voysey M, Clemens SAC, Madhi SA. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England) 2020; DOI: 10.1016/S0140-6736(20)32661-1.
    CrossrefPubMedGoogle Scholar
  • 60 Swadling L, Halliday J, Kelly C. et al. Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection. Vaccines 2016; 4
    PubMedGoogle Scholar
  • 61 Kelly C, Swadling L, Capone S. et al. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 2016; 63: 1455-1470
    CrossrefPubMedGoogle Scholar
  • 62 Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med 2010; 9: 90-97
    PubMedGoogle Scholar
  • 63 Becchetti C, Zambelli MF, Pasulo L. et al. COVID-19 in an international European liver transplant recipient cohort. Gut 2020; 69: 1832-1840
    CrossrefPubMedGoogle Scholar
  • 64 Donato MF, Invernizzi F, Lampertico P. et al. Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy. Clin Gastroenterol Hepatol 2020; 18: 2131-2133.e1
    CrossrefPubMedGoogle Scholar
  • 65 Belli LS, Duvoux C, Karam V. et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol 2020; 5: 724-725
    CrossrefPubMedGoogle Scholar
  • 66 Colmenero J, Rodríguez-Perálvarez M, Salcedo M. et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol 2020; DOI: 10.1016/j.jhep.2020.07.040.
    CrossrefPubMedGoogle Scholar
  • 67 Rinaldi M, Bartoletti M, Bussini L. et al. COVID-19 in solid organ transplant recipients: No difference in survival compared to general population. Transpl Infect Dis 2020; DOI: 10.1111/tid.13421.
    CrossrefPubMedGoogle Scholar
  • 68 Webb GJ, Moon AM, Barnes E. et al. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol 2020; 5: 643-644
    CrossrefPubMedGoogle Scholar
  • 69 Kates OS, Haydel BM, Florman SS. et al. Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa1097.
    CrossrefPubMedGoogle Scholar
  • 70 Chen X, Liao B, Cheng L. et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol 2020; 104: 7777-7785
    CrossrefPubMedGoogle Scholar
  • 71 Akalin E, Azzi Y, Bartash R. et al. Covid-19 and Kidney Transplantation. N Engl J Med 2020; 382: 2475-2477
    CrossrefPubMedGoogle Scholar
  • 72 Pereira MR, Mohan S, Cohen DJ. et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant 2020; 20: 1800-1808
    CrossrefPubMedGoogle Scholar
  • 73 Montagud-Marrahi E, Cofan F, Torregrosa JV. et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. Am J Transplant 2020; 20: 2958-2959
    CrossrefPubMedGoogle Scholar
  • 74 Fernández-Ruiz M, Andrés A, Loinaz C. et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant 2020; 20: 1849-1858
    CrossrefPubMedGoogle Scholar
  • 75 Brennan DC, Aguado JM, Potena L. et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: Evidence and potential mechanisms. Rev Med Virol 2013; 23: 97-125
    CrossrefPubMedGoogle Scholar
  • 76 Fix OK, Hameed B, Fontana RJ. et al. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020; 72: 287-304
    CrossrefPubMedGoogle Scholar
  • 77 Kim MY, Brennan DC, Shah P. General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection: Management for Transplant Recipients. Curr Transplant Reports 2020; DOI: 10.1007/s40472-020-00305-y.
    CrossrefPubMedGoogle Scholar
  • 78 Lee BT, Perumalswami PV, Im GY. et al. COVID-19 in Liver Transplant Recipients: An Initial Experience From the US Epicenter. Gastroenterology 2020; 159: 1176-1178.e2
    CrossrefPubMedGoogle Scholar
  • 79 Webb GJ, Marjot T, Cook JA. et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020; 5: 1008-1016
    CrossrefPubMedGoogle Scholar
  • 80 Stucchi RSB, Lopes MH, Kumar D. et al. Vaccine recommendations for solid-organ transplant recipients and donors. Transplantation 2018; 102: S72-S80
    CrossrefPubMedGoogle Scholar
  • 81 Mulley WR, Dendle C, Ling JEH. et al. Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Hear Lung Transplant 2018; 37: 844-852
    CrossrefPubMedGoogle Scholar